Lacosamide Tablet, Film Coated
Product Images NDC 62332-171

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 62332-171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Tablets (Lacosamide 100 mg)

Label for Lacosamide Tablets, USP 100 mg film-coated tablets by Alembic Pharmaceuticals Inc. The label states package contains 30 tablets, for oral use, with storage instructions and dosage directions referencing insert. It includes NDC 62332-172-30, barcode, and manufacturer information for Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.*

FDA Label Image

30 Tablets (Lacosamide 150 mg)

Lacosamide Tablets USP 150 mg film-coated oral tablets packaging label by Alembic Pharmaceuticals Inc. The label states the dosage strength (150 mg) prominently, contains the NDC number 62332-173-30, and notes the package includes 30 tablets. It includes storage instructions, manufacturer information for Alembic Pharmaceuticals, and a pharmacist attention note about the Medication Guide.*

FDA Label Image

30 Tablets (Lacosamide 200 mg)

Label for Lacosamide Tablets, USP 200 mg oral film-coated tablets, supplied in a package of 30 tablets. The label includes storage instructions, manufacturer details (Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.), and a barcode. It notes the package is child-resistant and includes a pharmacist warning to provide the medication guide with each prescription.*

FDA Label Image

30 Tablets (Lacosamide 50 mg)

Label for Lacosamide Tablets, USP 50 mg film-coated oral tablets. The label indicates 30 tablets per package and includes storage instructions, manufacturer details (Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.), and barcode information. The label is for a prescription drug and features a pharmacist warning to provide a medication guide to patients.*

FDA Label Image

Figure1 (Lacosamide Figure 1)

A bar chart titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose.' It compares the seizure reduction percentages of placebo vs. lacosamide at 200 mg/day and 400 mg/day across three studies, showing higher reductions with lacosamide in all cases.*

FDA Label Image

Figure2 (Lacosamide Figure 2)

A line graph titled 'Proportion of Patients by Responder Rate for Lacosamide and Placebo Groups in Studies 2, 3, and 4.' The vertical axis represents responder rate from -100% (worsening) to 100% (improvement), and the horizontal axis shows percent of patients from 0 to 100. Four lines depict different groups: placebo (N=359), lacosamide 200 mg/day (N=267), 400 mg/day (N=466), and 600 mg/day (N=202). The graph compares responder rates across these groups.*

FDA Label Image

Structure (Lacosamide Str)

Chemical structure diagram of the active ingredient lacosamide. The image shows the molecular arrangement including an acetyl group, amide linkages, and a phenyl ring consistent with the lacosamide molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.